Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

Abstract Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional characterization using mouse melanoma models, we show that the KE...

Full description

Bibliographic Details
Main Authors:	Douglas B. Fox, Richard Y. Ebright, Xin Hong, Hunter C. Russell, Hongshan Guo, Thomas J. LaSalle, Ben S. Wittner, Nicolas Poux, Joanna A. Vuille, Mehmet Toner, Nir Hacohen, Genevieve M. Boland, Debattama R. Sen, Ryan J. Sullivan, Shyamala Maheswaran, Daniel A. Haber
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-03-01
Series:	npj Precision Oncology
Online Access:	https://doi.org/10.1038/s41698-023-00362-3

Similar Items

Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator
by: Qingqing Xiao, et al.
Published: (2023-08-01)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
by: Yan Wu, et al.
Published: (2023-02-01)

Downregulation of Keap1 Confers Features of a Fasted Metabolic State
by: Elena V. Knatko, et al.
Published: (2020-10-01)

MCT4 blockade increases the efficacy of immune checkpoint blockade
by: Christian Schmidl, et al.
Published: (2023-10-01)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

Effects of Simultaneous Downregulation of PHD1 and Keap1 on Prevention and Reversal of Liver Fibrosis in Mice
by: Jing Liu, et al.
Published: (2018-05-01)

Isolation of circulating tumor cells
by: Jon F. Edd, et al.
Published: (2022-08-01)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
by: Jan Christoph Banck, et al.
Published: (2021-03-01)

Acquired Resistance to Immune Checkpoint Blockade Therapies
by: Xianda Zhao, et al.
Published: (2020-05-01)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Brian J. Ahn, et al.
Published: (2013-11-01)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
by: Xiuting Liu, et al.
Published: (2021-01-01)

Epigenetic checkpoint blockade: new booster for immunotherapy
by: Ziqiao Wang, et al.
Published: (2021-07-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
by: Lin AY, et al.
Published: (2022-02-01)

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
by: Shi, Alvin, et al.
Published: (2022)

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
by: Shi, Alvin, et al.
Published: (2021)

Molecular patterns of resistance to immune checkpoint blockade in melanoma
by: Martin Lauss, et al.
Published: (2024-04-01)

Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents
by: Arisa Djurian, et al.
Published: (2021-05-01)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
by: Maureen L. Drakes, et al.
Published: (2020-11-01)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
by: Chiara Cremolini, et al.
Published: (2021-03-01)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
by: Alejandra Martinez-Perez, et al.
Published: (2022-12-01)

Metabolic predictors of response to immune checkpoint blockade therapy
by: Ofir Shorer, et al.
Published: (2023-11-01)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
by: Melissa Sarver, et al.
Published: (2022-05-01)

Immune checkpoint alterations and their blockade in COVID-19 patients
by: Jiaxiong Tan, et al.
Published: (2022-10-01)

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
by: Pfirschke, Christina, et al.
Published: (2018)

Activation of the complement system sensitizes immune checkpoint blockade
by: Fei Shao, et al.
Published: (2023-03-01)

Combination approaches with immune checkpoint blockade in cancer therapy
by: Maarten Swart, et al.
Published: (2016-11-01)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
by: Elisa Peranzoni, et al.
Published: (2020-07-01)

Combination immune checkpoint blockade as an effective therapy for mesothelioma
by: Vanessa S. Fear, et al.
Published: (2018-10-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Predictors of responses to immune checkpoint blockade in advanced melanoma
by: N. Jacquelot, et al.
Published: (2017-09-01)

Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
by: Na Zhang, et al.
Published: (2020-11-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Microbial mechanisms to improve immune checkpoint blockade responsiveness
by: Matthew E. Griffin, et al.
Published: (2022-09-01)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
by: Michael Dougan
Published: (2017-11-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

New development of Immune checkpoints blockade in cancer immunotherapy
by: Wu Feixuan
Published: (2019-01-01)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
by: Haoxin Li, et al.
Published: (2019-09-01)